Dr. Virender Bhan has expertise in multiple sclerosis (MS) and other demyelinating disorders. His clinical focus is on the early diagnosis of MS, optimization of disease modifying therapies (DMT), advanced chemotherapy/biologics in aggressive MS and collaborative multidisciplinary treatment of progressive MS. He is director of the Dalhousie Multiple Sclerosis Research Unit

Dr. Bhan’s research interests include MS epidemiology, efficacy of disease modifying therapies, inhibitors of apoptosis as biomarkers for MS severity and DMT responsiveness, and the effect of co-morbidities in MS. He is active in multi-centre clinical trials for potential DMTs in relapsing and progressive MS.